{"filings":[{"id":443520,"accession_number":"0001104659-26-061237","cik":1802665,"company_name":"Harmony Biosciences Holdings, Inc.","ticker":"HRMY","form_type":"8-K","filed_at":"2026-05-14T20:31:08+00:00","items":["5.07"],"status":"ready","headline":"Harmony Biosciences shareholders elect four directors, ratify auditor, approve say-on-pay at 2026 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All four Class III director nominees elected: Geno Germano (44.96M for), Troy Ignelzi (32.81M), Ron Philip (31.83M), Andreas Wicki (25.11M).","Deloitte & Touche ratified as independent auditor for FY2026 with 49.39M for, 0.83M against, 0.17M abstain.","Say-on-pay advisory vote approved: 33.25M for, 13.04M against, 0.19M abstain; broker non-votes of 3.89M.","Quorum of 50.38M shares represented out of outstanding; all proposals passed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":1803935838.0923278,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95569,"accession_number":"0001104659-26-056786","cik":1802665,"company_name":"Harmony Biosciences Holdings, Inc.","ticker":"HRMY","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Harmony Biosciences Q1 revenue $215.4M (+17% YoY); reaffirms FY2026 guidance >$1B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 net product revenue $215.4M, up 17% YoY; diluted EPS $0.55 vs $0.78 in Q1 2025.","Reaffirmed FY2026 WAKIX net revenue guidance of $1.0B-$1.04B; on track for >$1B.","R&D expenses $69.4M (+101%) due to $32M upfront license payments; net income declined to $32.5M.","Filed patent infringement suit vs AET Pharma/Sandoz; acquired exclusive license to pitolisant patent expiring 2042.","Appointed Peter Anastasiou COO and Glenn Reicin CFO; cash and investments $870.5M as of March 31."],"consensus_eps_estimate":null,"consensus_eps_actual":0.55,"consensus_revenue_estimate":null,"consensus_revenue_actual":215387000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1803935838.0923278,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95568,"accession_number":"0001104659-26-042886","cik":1802665,"company_name":"Harmony Biosciences Holdings, Inc.","ticker":"HRMY","form_type":"8-K","filed_at":"2026-04-14T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Harmony Biosciences appoints Glenn Reicin as CFO; reaffirms 2026 revenue guidance of $1.0-$1.04B","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Sandip Kapadia steps down as CFO effective April 14, 2026 to pursue other career opportunities.","Glenn Reicin appointed CFO; previously CFO at Eccogene and Alladapt, Managing Director at Skyline Ventures.","New CFO: $500K base salary, 50% target bonus, $3M option grant vesting over four years.","Company reiterates 2026 net product revenue guidance of $1.0-$1.04 billion from WAKIX sales."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1803935838.0923278,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95567,"accession_number":"0001104659-26-038888","cik":1802665,"company_name":"Harmony Biosciences Holdings, Inc.","ticker":"HRMY","form_type":"8-K","filed_at":"2026-04-02T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Harmony Biosciences appoints Peter Anastasiou as COO; adds Troy Ignelzi to Board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Peter Anastasiou named SEVP and COO, effective April 2, 2026; resigns from Board.","Troy Ignelzi appointed Class III director, filling vacancy; will serve on Audit and Compensation Committees.","Antonio Gracias will not stand for re-election at 2026 annual meeting; term ends May 14, 2026.","Geno J. Germano nominated for election to Board at 2026 annual meeting.","Anastasiou receives $600K base salary, 55% bonus target, $3.7M option award with 4-year vest."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1803935838.0923278,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108728,"accession_number":"0001104659-26-018858","cik":1802665,"company_name":"Harmony Biosciences Holdings, Inc.","ticker":"HRMY","form_type":"8-K","filed_at":"2026-02-24T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Harmony Biosciences Q4 revenue $243.8M (+21% YoY); guides WAKIX to $1B+ in 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full-year 2025 WAKIX revenue $868.5M, up 22% YoY; Q4 GAAP EPS $0.38, adjusted EPS $0.57.","2026 net revenue guidance for WAKIX: $1.0-1.04B, targeting blockbuster status.","FDA approved pediatric cataplexy indication for WAKIX on Feb 13; commercial launch underway.","Settled with 3 additional generic filers, now 6 of 7; generics entry no earlier than March 2030 if pediatric exclusivity granted.","Pitolisant GR NDA submission on track for Q2 2026; orexin-2 agonist Phase 1 data expected mid-2026."],"consensus_eps_estimate":null,"consensus_eps_actual":2.71,"consensus_revenue_estimate":null,"consensus_revenue_actual":868453000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1803935838.0923278,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108727,"accession_number":"0001104659-26-002731","cik":1802665,"company_name":"Harmony Biosciences Holdings, Inc.","ticker":"HRMY","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Harmony Biosciences reports ~$868M FY2025 WAKIX revenue; guides $1.0-1.04B in 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary Q4 2025 WAKIX net revenue ~$243M; FY2025 ~$868M, up ~21% YoY.","2026 WAKIX net revenue guidance of $1.0-1.04B, on track for blockbuster status.","Pitolisant GR NDA submission expected 2Q 2026; PDUFA 1Q 2027; aims to extend franchise into 2040s.","Five ongoing Phase 3 reg. trials in CNS; topline data for pitolisant HD and EPX-100 in 2027.","ZYN002 program in Fragile X discontinued; 22q deletion syndrome indication no longer pursued."],"consensus_eps_estimate":null,"consensus_eps_actual":2.71,"consensus_revenue_estimate":null,"consensus_revenue_actual":868453000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1803935838.0923278,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125184,"accession_number":"0001104659-25-105942","cik":1802665,"company_name":"Harmony Biosciences Holdings, Inc.","ticker":"HRMY","form_type":"8-K","filed_at":"2025-11-04T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Harmony Biosciences Q3 revenue $239.5M (+29% YoY); raises FY2025 guidance to $845-865M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 net revenue $239.5M (WAKIX), +29% YoY; GAAP EPS $0.87, adjusted EPS $1.08.","Raised 2025 revenue guidance to $845-865M from $820-860M.","Record quarterly patient adds ~500, total ~8,100 average narcolepsy patients.","Cash & investments $778M; generated $106M cash flow in Q3.","Pipeline: pitolisant HD IND filed; Phase 3 narcolepsy/IH starts Q4; orexin-2 agonist first subject Q4."],"consensus_eps_estimate":null,"consensus_eps_actual":2.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":624677000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1803935838.0923278,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125183,"accession_number":"0001104659-25-101688","cik":1802665,"company_name":"Harmony Biosciences Holdings, Inc.","ticker":"HRMY","form_type":"8-K","filed_at":"2025-10-23T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Harmony Biosciences raises 2025 revenue guidance after Q3 WAKIX revenue of $239M (+29% YoY)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary Q3 2025 WAKIX net revenue of ~$239M, up 29% year-over-year.","Average patient count rose by ~500 to 8,100 in Q3, the largest quarterly increase ever.","2025 revenue guidance raised to $845-$865M from prior $820-$860M.","Full Q3 2025 earnings and conference call scheduled for November 4, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":2.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":624677000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1803935838.0923278,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141901,"accession_number":"0001104659-25-092776","cik":1802665,"company_name":"Harmony Biosciences Holdings, Inc.","ticker":"HRMY","form_type":"8-K","filed_at":"2025-09-24T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Harmony Biosciences' Phase 3 ZYN002 trial in Fragile X syndrome fails primary endpoint","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["RECONNECT study did not meet primary endpoint of improvement in social avoidance; higher than expected placebo response cited.","Study enrolled 215 patients aged 3 to <30 years; 1:1 randomization to ZYN002 or placebo over 18 weeks.","CEO Jeffrey Dayno reaffirms late-stage pipeline; Phase 3 trials for pitolisant HD in narcolepsy and idiopathic hypersomnia on track for Q4 2025.","Company describes itself as profitable and self-funding biotech with strong cash generation.","Fragile X syndrome has no FDA-approved therapies; company will conduct comprehensive data analysis."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1803935838.0923278,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141900,"accession_number":"0001558370-25-010182","cik":1802665,"company_name":"Harmony Biosciences Holdings, Inc.","ticker":"HRMY","form_type":"8-K","filed_at":"2025-08-05T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Harmony Biosciences Q2 revenue $200.5M (+16% YoY); EPS $0.68; reaffirms FY guidance $820-860M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net product revenue $200.5M (+16% YoY); GAAP net income $39.8M ($0.68 diluted EPS); non-GAAP adj. net income $53.8M ($0.92 diluted EPS).","Reaffirms 2025 revenue guidance $820M-$860M; added 400 average patients to 7,600 in Q2.","Phase 3 ZYN002 topline data in Fragile X syndrome on track for Q3 2025; targets ~80K U.S. patients.","Entered research collaboration with CiRC Biosciences for refractory epilepsy & narcolepsy; $15M upfront paid.","Settled ANDA litigation with Lupin; generic launch no earlier than Jan 2030 (or July 2030 with pediatric exclusivity)."],"consensus_eps_estimate":null,"consensus_eps_actual":1.46,"consensus_revenue_estimate":null,"consensus_revenue_actual":385222000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1803935838.0923278,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159829,"accession_number":"0001558370-25-008525","cik":1802665,"company_name":"Harmony Biosciences Holdings, Inc.","ticker":"HRMY","form_type":"8-K","filed_at":"2025-06-11T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Harmony Biosciences Presents Preclinical Data for BP1.15205 OX2R Agonist in Narcolepsy","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Data presented at SLEEP 2025 showed significant wake-promoting and cataplexy-suppressing effects in transgenic mouse model of narcolepsy type 1.","BP1.15205 demonstrated high potency (EC50=0.015 nM) and >600-fold selectivity over human OX1R.","No adverse events were observed in 3-month GLP toxicity study at doses up to 300 mg/kg/day.","First-in-human study planned for 2H 2025 with topline data anticipated in 2026.","IMPD application with EMA being completed; IND for BP1.15205 to be filed with FDA."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1803935838.0923278,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159828,"accession_number":"0001558370-25-008415","cik":1802665,"company_name":"Harmony Biosciences Holdings, Inc.","ticker":"HRMY","form_type":"8-K","filed_at":"2025-06-05T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Harmony settles Lupin ANDA litigation; generic WAKIX entry delayed to 2030","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Lupin receives license to launch generic WAKIX no earlier than January 2030 (July 2030 with pediatric exclusivity).","Litigation in U.S. District Court for Delaware dismissed as part of the agreement.","Harmony will continue patent infringement litigation against other ANDA filers seeking generic WAKIX.","U.S. Patent Office PTAB previously declined to institute reexamination of Harmony's polymorph patent, affirming its validity.","Harmony is developing next-generation pitolisant formulations with patents extending potential exclusivity to 2044."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1803935838.0923278,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159827,"accession_number":"0001558370-25-007894","cik":1802665,"company_name":"Harmony Biosciences Holdings, Inc.","ticker":"HRMY","form_type":"8-K","filed_at":"2025-05-15T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Harmony Biosciences shareholders re-elect three Class II directors and ratify auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected Class II directors: Juan Sabater (25.9M for, 18.0M withheld), Gary Sender (35.0M for, 8.9M withheld), Linda Szyper (34.9M for, 9.0M withheld).","Ratified Deloitte & Touche as independent auditor for FY2025 with 44.7M for, 738.6K against, 17.1K abstain.","Total shares represented at meeting: 45,446,787, constituting a quorum."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.0,"calibrated_materiality_score":0.0,"market_cap_usd":1803935838.0923278,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159826,"accession_number":"0001558370-25-006393","cik":1802665,"company_name":"Harmony Biosciences Holdings, Inc.","ticker":"HRMY","form_type":"8-K","filed_at":"2025-05-06T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Harmony Biosciences reports 20% Q1 revenue growth; reaffirms 2025 guidance $820-860M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 net revenue $184.7M, +20% YoY; GAAP net income $45.6M ($0.78 diluted EPS).","Non-GAAP adjusted net income $60.4M ($1.03 diluted EPS) vs $50.7M ($0.88) YoY.","Reaffirms FY2025 revenue guidance $820-$860M; cash and investments >$600M.","ZYN002 Phase 3 in Fragile X completed recruitment; topline data on track for Q3 2025.","Pitolisant HD Phase 3 registrational trials in narcolepsy & IH on track to initiate Q4 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":0.78,"consensus_revenue_estimate":null,"consensus_revenue_actual":184733000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1803935838.0923278,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159825,"accession_number":"0001558370-25-004358","cik":1802665,"company_name":"Harmony Biosciences Holdings, Inc.","ticker":"HRMY","form_type":"8-K","filed_at":"2025-04-03T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Harmony Biosciences appoints Ron Philip to Board of Directors effective April 2, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Ron Philip, age 51, appointed as Class III director filling vacancy from Jack Bech Nielsen's resignation.","Philip will serve on the Audit Committee and Nominating and Corporate Governance Committee.","He is current CEO of Orbital Therapeutics and former CEO of Spark Therapeutics (April 2022–September 2024).","Philip has 30 years of biotech experience including roles at Pfizer, Wyeth, and Merck.","Board determined Philip qualifies as independent under Nasdaq standards; standard director compensation applies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":1803935838.0923278,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178188,"accession_number":"0001558370-25-003502","cik":1802665,"company_name":"Harmony Biosciences Holdings, Inc.","ticker":"HRMY","form_type":"8-K","filed_at":"2025-03-24T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Harmony Biosciences names Takeda veteran Adam Zaeske as CCO; Dierks steps down","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jeffrey Dierks steps down as CCO effective March 31, 2025; receives $476,215 cash and accelerated vesting for 2025 awards.","Adam Zaeske appointed as EVP and CCO effective March 31, 2025; previously Head of Central, South, and Eastern Europe at Takeda.","Zaeske managed a $2B business across 25 countries with 900 employees; delivered 3 consecutive years of double-digit growth.","Company reaffirms 2025 revenue guidance and states WAKIX is a $1B+ opportunity in adult narcolepsy alone.","Zaeske brings 25 years of pharma experience, including rare disease and neurology launches."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1803935838.0923278,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178187,"accession_number":"0001558370-25-001439","cik":1802665,"company_name":"Harmony Biosciences Holdings, Inc.","ticker":"HRMY","form_type":"8-K","filed_at":"2025-02-25T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Harmony Biosciences Q4 2024 net revenue $201.3M, FY $714.7M; guides 2025 $820-860M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2024 net product revenue $201.3M (+20% YoY); FY 2024 net revenue $714.7M (+23% YoY).","Q4 GAAP net income $49.5M ($0.85 diluted EPS); non-GAAP adjusted net income $63.0M ($1.08 diluted EPS).","2025 WAKIX net revenue guidance set at $820M-$860M; on track for potential $1B+ narcolepsy opportunity.","Phase 3 topline for ZYN002 in Fragile X syndrome expected Q3 2025; pitolisant HD trials to start Q4 2025.","Settled first ANDA litigation with Novugen; generic license begins Jan 2030 or earlier under certain conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":2.51,"consensus_revenue_estimate":null,"consensus_revenue_actual":714734000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1803935838.0923278,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178186,"accession_number":"0001558370-25-000157","cik":1802665,"company_name":"Harmony Biosciences Holdings, Inc.","ticker":"HRMY","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Harmony Biosciences: Q4 WAKIX revenue ~$201M, FY2024 ~$714M; guides 2025 $820-860M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary Q4 2024 net product revenue ~$201M (vs $168.4M Q4 2023); FY2024 ~$714M (vs $582M, +23% YoY).","2025 net revenue guidance of $820-860M, implying continued growth toward $1B+ opportunity.","Pipeline catalysts: FDA decision on pitolisant sNDA for idiopathic hypersomnia expected Q1 2025; potential approval in 2025.","Phase 3 topline data for ZYN002 in Fragile X syndrome expected Q3 2025; Pitolisant-HD Phase 3 in narcolepsy to start Q4 2025.","Average patients on WAKIX increased to ~7,100 in Q4 2024, up ~300 sequentially."],"consensus_eps_estimate":null,"consensus_eps_actual":2.51,"consensus_revenue_estimate":null,"consensus_revenue_actual":714734000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1803935838.0923278,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194858,"accession_number":"0001104659-24-113484","cik":1802665,"company_name":"Harmony Biosciences Holdings, Inc.","ticker":"HRMY","form_type":"8-K","filed_at":"2024-11-01T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Secondary offering of 8M shares by certain shareholders; company receives no proceeds","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Selling Shareholders sold 8,000,000 shares of common stock in a registered public offering.","Underwriters granted a 30-day option to purchase up to 1,200,000 additional shares.","J.P. Morgan Securities LLC acted as the sole underwriter for the offering.","Company will not receive any proceeds from the sale; all net proceeds go to Selling Shareholders.","Offering closed on November 1, 2024, under an Underwriting Agreement dated October 30, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1803935838.0923278,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194857,"accession_number":"0001558370-24-013802","cik":1802665,"company_name":"Harmony Biosciences Holdings, Inc.","ticker":"HRMY","form_type":"8-K","filed_at":"2024-10-29T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Harmony Biosciences Q3 net revenue $186M (+16% YoY); reiterates FY2024 guidance $700-720M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP net income $46.1M ($0.79 diluted EPS) vs $38.5M ($0.63) in Q3 2023; non-GAAP adjusted EPS $1.03.","Average WAKIX patients ~6,800 (+250 sequentially); cumulative net revenue surpasses $2B since 2019 launch.","On track to submit sNDA for pitolisant in idiopathic hypersomnia in Q4 2024; LTS data show sustained efficacy.","Pipeline: EPX-100 Phase 3 for Dravet syndrome (data 2026); Phase 3 for LGS to start by year-end; ZYN-002 topline mid-2025.","Reiterates FY2024 net product revenue guidance of $700-$720 million."],"consensus_eps_estimate":null,"consensus_eps_actual":1.66,"consensus_revenue_estimate":null,"consensus_revenue_actual":513467000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1803935838.0923278,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194856,"accession_number":"0001558370-24-013103","cik":1802665,"company_name":"Harmony Biosciences Holdings, Inc.","ticker":"HRMY","form_type":"8-K","filed_at":"2024-10-01T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Harmony Biosciences highlights best-in-class orexin-2 agonist, $3B revenue goal at Investor Day","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["BP1.15205 orexin-2 agonist shows highest potency vs. all publicly disclosed competitors, potential best-in-class.","Pitolisant in IH: mean ESS improvement ~9 points beyond 1 year; majority achieve normal wakefulness; sNDA on track Q4 2024.","Pitolisant-HD safety data up to 5x highest WAKIX dose; target PDUFA 2028; market research anticipates high uptake.","Fragile X (ZYN-002): 40% median improvement in social avoidance (p=0.027) in methylated patients; Phase 3 topline mid-2025.","EPX-100 in Dravet syndrome shows favorable safety vs approved drugs; topline 2026; Phase 3 LGS starts 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1803935838.0923278,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211148,"accession_number":"0001558370-24-010960","cik":1802665,"company_name":"Harmony Biosciences Holdings, Inc.","ticker":"HRMY","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Harmony Q2 net revenue $172.8M (+29% YoY); non-GAAP EPS $1.05 vs $0.76; FY guidance reaffirmed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net product revenue $172.8M for Q2 2024, up 29% from $134.2M in Q2 2023.","GAAP net income $11.6M ($0.20 diluted EPS) vs $34.3M ($0.56) prior year; non-GAAP adjusted net income $60.6M ($1.05 diluted EPS) vs $45.9M ($0.76).","Average patients on WAKIX increased sequentially by ~250 to approximately 6,550 for the quarter.","FY 2024 net product revenue guidance reiterated at $700-$720 million.","FDA approved WAKIX for pediatric narcolepsy (EDS) on June 21, 2024; commercial launch began July 1."],"consensus_eps_estimate":null,"consensus_eps_actual":0.87,"consensus_revenue_estimate":null,"consensus_revenue_actual":327429000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1803935838.0923278,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211147,"accession_number":"0001558370-24-009642","cik":1802665,"company_name":"Harmony Biosciences Holdings, Inc.","ticker":"HRMY","form_type":"8-K","filed_at":"2024-07-01T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Board member Jack Bech Nielsen resigns for health reasons; subsidiary Zynerba renamed","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jack Bech Nielsen resigned from the Board effective June 27, 2024 due to health reasons; no disagreements with the company.","Wholly owned subsidiary Zynerba Pharmaceuticals, Inc. renamed to Harmony Biosciences Management, Inc. effective July 1, 2024.","No financial or operational impact disclosed from either event.","Ticker: HRMY."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1803935838.0923278,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229683,"accession_number":"0001558370-24-008734","cik":1802665,"company_name":"Harmony Biosciences Holdings, Inc.","ticker":"HRMY","form_type":"8-K","filed_at":"2024-05-29T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Harmony Biosciences shareholders elect all three Class I directors and ratify Deloitte as auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Jeffrey S. Aronin, R. Mark Graf, and Jeffrey M. Dayno elected as Class I directors with votes ranging from 18.3M to 20.6M for.","Ratification of Deloitte & Touche LLP as independent auditor for 2024 passed with 40.2M votes for, 495k against, 12,722 abstain.","Approximately 40.7M shares (quorum) represented at the 2024 Annual Meeting held May 29, 2024.","All director nominees will serve until the 2027 Annual Meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1803935838.0923278,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229682,"accession_number":"0001558370-24-006594","cik":1802665,"company_name":"Harmony Biosciences Holdings, Inc.","ticker":"HRMY","form_type":"8-K","filed_at":"2024-05-03T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Kumar Budur promoted to EVP and Chief Medical & Scientific Officer at Harmony Biosciences","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointed EVP & Chief Medical & Scientific Officer effective May 1, 2024.","Annual salary raised from $500,000 to $575,000; target bonus remains 50% of salary.","Receives 75,000 RSUs and 75,000 stock options vesting over four years.","Dr. Budur had been Chief Medical Officer; biography previously disclosed in proxy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":1803935838.0923278,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229681,"accession_number":"0001558370-24-006200","cik":1802665,"company_name":"Harmony Biosciences Holdings, Inc.","ticker":"HRMY","form_type":"8-K","filed_at":"2024-04-30T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Harmony Biosciences Q1 revenue $154.6M (+30% YoY); reaffirms FY2024 guidance $700-720M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 net revenue $154.6M (+30% YoY); GAAP EPS $0.67, adjusted EPS $0.88.","Reaffirmed FY 2024 net revenue guidance of $700-720M.","Pipeline: sNDA for pitolisant in IH planned H2 2024; pediatric narcolepsy PDUFA June 21, 2024.","Licensed TPM-1116 (orexin-2 agonist) for narcolepsy; IND expected mid-2025.","Acquired Epygenix for rare epilepsy; clemizole Dravet/LGS pivotal trial topline 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":0.67,"consensus_revenue_estimate":null,"consensus_revenue_actual":154615000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1803935838.0923278,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229680,"accession_number":"0001558370-24-004945","cik":1802665,"company_name":"Harmony Biosciences Holdings, Inc.","ticker":"HRMY","form_type":"8-K","filed_at":"2024-04-11T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Harmony Biosciences obtains exclusive license for orexin-2 receptor agonist from Bioprojet","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Upfront fee $25.5M; development/regulatory milestones up to $127.5M, sales milestones up to $240M.","Licensed compound is pre-clinical; IND expected H2 2025 for narcolepsy and other indications.","Exclusive rights to develop, manufacture, commercialize in US and Latin America.","Amended 2017 and 2022 LCAs with Bioprojet to remove exclusivity of efforts provisions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1803935838.0923278,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248192,"accession_number":"0001558370-24-001465","cik":1802665,"company_name":"Harmony Biosciences Holdings, Inc.","ticker":"HRMY","form_type":"8-K","filed_at":"2024-02-22T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Harmony Biosciences Q4 2023 revenue $168.4M, guides 2024 revenue $700-720M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["WAKIX net revenue $168.4M in Q4 2023 (+31% YoY); full year $582.0M (+33%).","GAAP diluted EPS $0.45 vs $0.79 YoY; non-GAAP adjusted EPS $0.73 vs $1.01.","FDA granted priority review for WAKIX in pediatric narcolepsy; PDUFA June 21, 2024.","2024 net product revenue guidance $700-720M, up from ~$582M in 2023.","Repurchased 3.2M shares for $100M in 2023; $150M remaining authorization."],"consensus_eps_estimate":null,"consensus_eps_actual":2.13,"consensus_revenue_estimate":null,"consensus_revenue_actual":582022000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1803935838.0923278,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248191,"accession_number":"0001558370-24-000128","cik":1802665,"company_name":"Harmony Biosciences Holdings, Inc.","ticker":"HRMY","form_type":"8-K","filed_at":"2024-01-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Harmony Biosciences reports Q4 net product revenue ~$168M, FY2023 ~$582M; 2024 guidance $700-720M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary Q4 net product revenue ~$168M, up ~31% YoY; FY2023 ~$582M, up ~33% YoY.","Average WAKIX patients ~6,150 in Q4 2023; 2024 target ~7,000 patients.","2024 net product revenue guidance of $700M to $720M.","Repurchased ~1.8M shares for $50M in Q4 2023; $150M remaining authorization."],"consensus_eps_estimate":null,"consensus_eps_actual":2.13,"consensus_revenue_estimate":null,"consensus_revenue_actual":582022000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1803935838.0923278,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":265659,"accession_number":"0001558370-23-019624","cik":1802665,"company_name":"Harmony Biosciences Holdings, Inc.","ticker":"HRMY","form_type":"8-K/A","filed_at":"2023-12-07T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Harmony files Zynerba FY2022 audited financials; net loss $35M, accumulated deficit $274.5M","summary_kind":"llm","event_type":"m_and_a","confidence":"medium","bullets":["Zynerba FY2022 net loss $35.0M ($0.82 loss per share); no revenue; R&D expense $21.1M, G&A $14.2M.","Cash and equivalents $50.6M at Dec 31, 2022; sufficient to fund operations to mid-2024 per management.","Acquisition closed Oct 10, 2023; pro forma combined statements filed as Exhibit 99.3 (not included in this text).","Zynerba clinical-stage pipeline targets FXS and 22q deletion syndrome; deferred Phase 3 ASD program."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1803935838.0923278,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}